About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Companion Diagnostics Market Size to reach 15.87 Billion by 2032
Companion Diagnostics Market

Companion Diagnostics Market Size, Share & Trends Analysis Report By Technology (Polymerase Chain Reaction (PCR) , Next-generation Sequencing (NGS), Immunohistochemistry, In Situ Hybridization, Others), By Indication (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Virology Diseases, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH946DR
Last Updated : February 01, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Companion Diagnostics Market Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    4. U.S.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR) 
          1. By Value
        3. Next-generation Sequencing (NGS)
          1. By Value
        4. Immunohistochemistry
          1. By Value
        5. In Situ Hybridization
          1. By Value
        6. Others
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Cardiovascular Diseases
          1. By Value
        5. Central Nervous System Disorders
          1. By Value
        6. Virology Diseases
          1. By Value
        7. Others
          1. By Value
    5. Canada
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    4. U.K.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR) 
          1. By Value
        3. Next-generation Sequencing (NGS)
          1. By Value
        4. Immunohistochemistry
          1. By Value
        5. In Situ Hybridization
          1. By Value
        6. Others
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Cardiovascular Diseases
          1. By Value
        5. Central Nervous System Disorders
          1. By Value
        6. Virology Diseases
          1. By Value
        7. Others
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    4. China
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR) 
          1. By Value
        3. Next-generation Sequencing (NGS)
          1. By Value
        4. Immunohistochemistry
          1. By Value
        5. In Situ Hybridization
          1. By Value
        6. Others
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Cardiovascular Diseases
          1. By Value
        5. Central Nervous System Disorders
          1. By Value
        6. Virology Diseases
          1. By Value
        7. Others
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    4. UAE
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR) 
          1. By Value
        3. Next-generation Sequencing (NGS)
          1. By Value
        4. Immunohistochemistry
          1. By Value
        5. In Situ Hybridization
          1. By Value
        6. Others
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Cardiovascular Diseases
          1. By Value
        5. Central Nervous System Disorders
          1. By Value
        6. Virology Diseases
          1. By Value
        7. Others
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR) 
        1. By Value
      3. Next-generation Sequencing (NGS)
        1. By Value
      4. Immunohistochemistry
        1. By Value
      5. In Situ Hybridization
        1. By Value
      6. Others
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology
        1. By Value
      3. Autoimmune Diseases
        1. By Value
      4. Cardiovascular Diseases
        1. By Value
      5. Central Nervous System Disorders
        1. By Value
      6. Virology Diseases
        1. By Value
      7. Others
        1. By Value
    4. Brazil
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR) 
          1. By Value
        3. Next-generation Sequencing (NGS)
          1. By Value
        4. Immunohistochemistry
          1. By Value
        5. In Situ Hybridization
          1. By Value
        6. Others
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology
          1. By Value
        3. Autoimmune Diseases
          1. By Value
        4. Cardiovascular Diseases
          1. By Value
        5. Central Nervous System Disorders
          1. By Value
        6. Virology Diseases
          1. By Value
        7. Others
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Companion Diagnostics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Abbott
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Agilent Technologies
    3. Hoffmann-La Roche Ltd
    4. Biomerieux SA
    5. Qiagen NV
    6. Almac Group
    7. Danaher Corporation
    8. Illumina, Inc.
    9. Myriad Genetics, Inc.
    10. Sysmex Corporation
    11. Thermo Fisher Scientific Inc.
    12. Abnova Corporation
    13. Guardant Health, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Clinical Diagnostics Market Size The global clinical diagnostics market size was valued at USD 84.18 billion in 2024 and is projected to reach from USD 98.21 billion in 2025 to USD 187.78 billion by 2033, exhibiting a CAGR of 6.48% during the f
Buy Now
Global Report
The global COVID-19 diagnostics market was valued at USD 84500 million in 2020 and is expected to grow at 3.2% CAGR during the forecast period. In 2019, a new coronavirus strain was identified to have caused a disease outbreak originating in Wuhan,
Buy Now
Global Report
The global sepsis diagnostics market size was valued at USD 685 million in 2022. It is expected to reach USD 1,427.44 million by 2031 at a CAGR of 8.5% during the projected period (2023–2031). Factors such as increasing prevalence of
Buy Now
Global Report
TB Diagnostics Market Size & Trends The global TB diagnostics market size was valued at USD 1.33 billion in 2021 and it is projected to reach a valuation of USD 2.14 billion by 2030 growing at a CAGR of 5.56% during the forecast period (2022–203
Buy Now
Global Report
The global transplant diagnostics market size was valued at USD 3,550 million in 2019 and is expected to grow with a CAGR of 7.4% during the forecast period, 2020–2029. Organ transplantation is a surgical procedure of removing healthy org
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.